Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Combination vaccines industry 360º synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Age group trends
2.1.4 Technology trends
2.1.5 Application trends
2.1.6 End-use trends
Chapter 3 Combination Vaccines Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of infectious diseases
3.2.1.2 Rising focus on preventive healthcare
3.2.1.3 Enhance vaccine coverage and improved patient compliance
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory requirements
3.2.2.2 High development and product costs
3.3 Growth potential analysis
3.3.1 By age group
3.3.2 By technology
3.3.3 By application
3.3.4 By end-use
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6 Potential future approaches for producing combination vaccines
3.7 Combination vaccines available in U.S.
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
4.6 Strategy outlook matrix
Chapter 5 Combination Vaccines Market Size and Forecast, By Age group (USD Million)
5.1 Key trends, by age group
5.2 Pediatric
5.3 Adult
Chapter 6 Combination Vaccines Market Size and Forecast, By Technology (USD Million)
6.1 Key trends, by technology
6.2 Conjugate
6.3 Live
6.4 Recombinant
6.5 Inactivated
6.6 Toxoid
6.7 Other Technologies
Chapter 7 Combination Vaccines Market Size and Forecast, By Application (USD Million)
7.1 Key trends, by application
7.2 Diphtheria, Tetanus, and Pertussis (DTP)
7.3 Polio
7.4 Hepatitis B
7.5 Influenza
7.6 Hepatitis A
7.7 Varicella (chickenpox)
7.8 Measles, Mumps, and Rubella (MMR)
7.9 Other Applications
Chapter 8 Combination Vaccines Market Size and Forecast, By End-use (USD Million)
8.1 Key trends, by end-use
8.2 Hospitals
8.2.1 Public Hospitals
8.2.2 Private Hospitals
8.3 Clinics
8.4 Other end-users
Chapter 9 Combination Vaccines Market Size and Forecast, By Region (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Sanofi Pasteur
10.2 GlaxoSmithKline (GSK)
10.3 Merck & Co., Inc.
10.4 Panacea Biotec
10.5 Sinovac Biotech
10.6 Serum Institute of India
10.7 Beijing Minhai Biological Technology Co., Ltd.
10.8 Novavax
